RE:RE:RE:RE:RE:RE:F4 formulationYes, but even if NASH results are incredible, the reps can’t detail on that data without a label expansion from the FDA.
They can publish the data and have experts deliver talks but can’t detail at the office level.
I wonder if he is referring to the change in formulation. Otherwise, he is simply quite confident that the label expansion will be allowed.
bfw
jfm1330 wrote: Very intriguing comment made by Tanguay in the Q&A:
" You will see in the coming weeks and months a very different approach to Egrifta"
He then says its related to a new campaign to promote Egrifta and the F4, but he also said that F4 will only start next fall. So why a very different approach in the coming weeks and months. The fall is not in the coming weeks and months. But NASH results will come in the coming weeks, or months. In fact they said in about six weeks.
I think he said a lot there without giving any specifics.